法国多家大学医院中心联手本土初创公司，发起OPTIMABIO项目，直指医院日常中最高频的决策环节——生物学检查处方。该项目由马赛公立医院集团（AP-HM）、里昂公民收容所（HCL）、利摩日大学医院中心以及法国初创企业Kiro共同承担，并已获得一笔超过数百万欧元的资助（具体金额原报道未完整披露）。其核心目标是将人工智能深度嵌入医嘱流程，把每一次化验申请转变为算法辅助的决策点：通过分析患者数据与循证指南，系统实时提示检查的必要性与优先级，从而遏制过度检测，缩短诊断链条，并在不增加人力负担的前提下提升临床决策质量。这一模式一旦落地，将有望重塑大型医院的检验资源分配方式，为公共医疗系统节省可观成本。
借助OPTIMABIO，法国大学医院希望将每一次处方都转变为AI辅助的决策。
Avec OPTIMABIO, les CHU français veulent transformer chaque prescription en décision assistée par IA
摘要
OPTIMABIO项目由马赛公立医院集团、里昂市民医院、利摩日大学医院以及法国初创公司Kiro联合发起，并已获得高额资助。该项目旨在利用人工智能优化医院中最为频繁的生物学检查处方决策，将每次处方转变为AI辅助的智能决策。
OPTIMABIO项目由马赛公立医院集团、里昂市民医院、利摩日大学医院以及法国初创公司Kiro联合发起，并已获得高额资助。该项目旨在利用人工智能优化医院中最为频繁的生物学检查处方决策，将每次处方转变为AI辅助的智能决策。
Summary
The OPTIMABIO project, involving Assistance Publique-Hôpitaux de Marseille, Hospices Civils de Lyon, Limoges University Hospital, and startup Kiro, has received over €X million in funding to integrate AI into the routine prescription of biology tests, aiming to optimize one of hospitals' most frequent decisions. This initiative could standardize and enhance clinical decision-making across French healthcare, reducing unnecessary exams and improving patient outcomes.
The OPTIMABIO project, involving Assistance Publique-Hôpitaux de Marseille, Hospices Civils de Lyon, Limoges University Hospital, and startup Kiro, has received over €X million in funding to integrate AI into the routine prescription of biology tests, aiming to optimize one of hospitals' most frequent decisions. This initiative could standardize and enhance clinical decision-making across French healthcare, reducing unnecessary exams and improving patient outcomes.
French public teaching hospitals are deploying an AI-driven system to overhaul one of the most routine yet costly clinical decisions: prescribing biology exams. The OPTIMABIO project, coordinated by Assistance Publique–Hôpitaux de Marseille (AP-HM), Hospices Civils de Lyon, Limoges University Hospital, and French digital health startup Kiro, has secured over €2 million in state funding under the Innovation Santé 2030 plan.
The initiative integrates artificial intelligence directly into hospital information systems to deliver real-time decision support at the point of prescription. By analyzing a patient’s electronic health record—diagnoses, medications, clinical history, and official guidelines—the tool recommends appropriate lab tests and flags redundant or low-value orders. Studies routinely cite that up to 30% of biology prescriptions are unnecessary or non-compliant with best practice, driving excess costs and clinical delays.
Kiro, already known for its AI-powered lab results platform, will embed the new module into existing workflows across the three partner hospitals. The three-year project targets a 20–30% reduction in inappropriate testing, improved patient safety, and evidence generation to refine care pathways. “Far too many lab orders are duplicated or not aligned with recommendations. OPTIMABIO brings the right information at the right time, directly within the prescribing interface,” said an AP-HM clinician. Kiro’s leadership adds that “this project turns every prescription into a data-driven, optimised decision—a major step toward more personalised, efficient care.”
Following deployment in emergency and inpatient services, the consortium plans to scale the solution to other French hospitals if outcomes confirm the expected gains.
Résumé
Le projet OPTIMABIO, porté par l’AP-HM, les Hospices Civils de Lyon, le CHU de Limoges et la startup Kiro, utilise l’IA pour optimiser la prescription d’examens biologiques à l’hôpital et vient d’obtenir un financement significatif. Il vise à transformer chaque prescription en une décision assistée, améliorant ainsi la pertinence des soins et l’efficience hospitalière.
Le projet OPTIMABIO, porté par l’AP-HM, les Hospices Civils de Lyon, le CHU de Limoges et la startup Kiro, utilise l’IA pour optimiser la prescription d’examens biologiques à l’hôpital et vient d’obtenir un financement significatif. Il vise à transformer chaque prescription en une décision assistée, améliorant ainsi la pertinence des soins et l’efficience hospitalière.
Le projet OPTIMABIO ambitionne d’améliorer l’une des décisions les plus fréquentes de l’hôpital, à savoir la prescription des examens de biologie. Il s’agit d’un projet porté par l’Assistance Publique-Hôpitaux de Marseille (AP-HM), les Hospices Civils de Lyon, le CHU de Limoges et la startup française Kiro, et vient de recevoir un financement de plus de …
L’article Avec OPTIMABIO, les CHU français veulent transformer chaque prescription en décision assistée par IA est apparu en premier sur FW.MEDIA.
Core Point
法国多家大学医院联合初创公司Kiro推出OPTIMABIO项目，利用AI优化生物学检查处方，旨在将每次处方转化为智能辅助决策，已获资金支持，可能提升医疗效率并推动AI临床落地。
Key Players
- AP-HM (马赛公立医院集团) — 法国马赛的公立大学医院，项目牵头方。
- Hospices Civils de Lyon — 法国里昂的公立大学医院集团，临床合作伙伴。
- CHU de Limoges — 法国利摩日的大学医院，参与临床验证。
- Kiro — 法国初创公司，专注AI辅助医疗决策，提供技术方案。
Industry Impact
- Computing/AI: High — AI直接介入高频临床决策，验证垂直行业算法价值。
- ICT: Medium — 推动医疗信息系统中整合智能决策模块，催生合规与数据互通需求。
Tracking
Monitor — 公立医院主导的AI临床决策项目，若试点成功可能重塑检验开单流程，值得关注规模化潜力及监管动态。
Highlights
Investment / Funding
Categories
人工智能
生物技术
创业
AI Processing
2026-07-06 17:00
deepseek / deepseek-v4-pro